Company Evaxion A/S

Equities

EVAX

US29970R3030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:30:00 10/03/2026 +04			5-day change	1st Jan Change
3.080 ^USD	-4.35%		-2.84%	-35.43%

03-09	European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading	MT
03-06	European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Down 5% for Week	MT

Business description: Evaxion A/S

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Number of employees: 46

Sales by Activity: Evaxion A/S

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Biotechnology	-	-	73K	3.34M	-

See all business segments

Geographical breakdown of sales: Evaxion A/S

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Denmark	-	-	73K	3.34M	-

See all geographic segments

Executive Committee: Evaxion A/S

Manager	Title	Age	Since
Helena Tayton-Martin CEO	Chief Executive Officer	59	24/11/2025
Andreas Mattsson PRN	Corporate Officer/Principal	49	11/08/2008
Thomas Schmidt DFI	Director of Finance/CFO	53	01/11/2024
Birgitte Rono CEO	Chief Executive Officer	49	01/07/2025
Mads Vindahl Kronborg IRC	Investor Relations Contact	-	-

See EVAXION A/S governance

Composition of the Board of Directors: Evaxion A/S

Director	Title	Age	Since
Marianne Søgaard CHM	Chairman	58	25/11/2020
Roberto Prego Pineda BRD	Director/Board Member	56	01/01/2018
Lars Holtug BRD	Director/Board Member	68	25/05/2021
Lars Wegner CHM	Chairman	52	01/01/2013

Composition of the Board of Directors

Shareholders: Evaxion A/S

Name	Equities	%	Valuation
MERCK & CO., INC. 19.22 %	1,214,126	19.22 %	4 M $
Ikarian Capital LLC 1.183 %	74,698	1.183 %	237 540 $
PSM Vermögensverwaltung GmbH Langen v.d.Goltz, Dr. Prinz 0.7916 %	50,000	0.7916 %	159 000 $
Point72 Asset Management LP 0.524 %	33,100	0.524 %	105 258 $
RhumbLine Advisers LP 0.3339 %	21,090	0.3339 %	67 066 $

Name	Equities	%	Valuation
MERCK & CO., INC. 19.22 %	60,706,348	19.22 %	19 M $
Andreas Mattsson 1.942 %	6,134,918	1.942 %	2 M $
Marianne Søgaard 1.705 %	5,383,415	1.705 %	2 M $
Christian Kanstrup 1.109 %	3,502,844	1.109 %	1 M $
Thomas Schmidt 0.3067 %	968,600	0.3067 %	308 015 $

List of EVAXION A/S shareholders

Company details: Evaxion A/S

Evaxion Biotech A/S

Dr. Neergaards Vej 5F

2970, Hoersholm

http://www.evaxion-biotech.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EVAXION A/S	-4.35%	-2.84%	+63.83%	-94.74%	25.69M
LONZA GROUP AG	+1.28%	-2.24%	-6.91%	-5.13%	44.96B
BEONE MEDICINES AG	+0.39%	-3.84%	+22.35%	+38.67%	33.54B
CELLTRION, INC.	-4.00%	-14.47%	+15.30%	+41.71%	30.24B
IQVIA HOLDINGS INC.	+2.33%	+2.46%	-6.83%	-12.01%	29.97B
REVOLUTION MEDICINES, INC.	+1.41%	-1.80%	+154.50%	+359.86%	19.78B
ASCENDIS PHARMA A/S	-0.30%	-0.90%	+64.62%	+120.53%	14.73B
MEDPACE HOLDINGS, INC.	+1.69%	+4.61%	+43.79%	+154.56%	13.58B
EUROFINS SCIENTIFIC SE	+1.51%	-2.48%	+23.43%	+1.67%	12.97B
IONIS PHARMACEUTICALS, INC.	+1.78%	-8.05%	+122.89%	+116.80%	12.45B
Average	+0.17%	-3.21%	+49.70%	+72.19%	21.22B
Weighted average by Cap.	+0.50%	-3.65%	+33.61%	+68.00%